Impact and mechanisms of cognitive behavioral therapy for insomnia on fatigue among cancer survivors: a secondary analysis of a randomized controlled trial.

STUDY OBJECTIVES

Cancer-related fatigue is one of the most common symptoms in cancer survivors. Cognitive behavioral therapy for insomnia (CBT-I) can improve fatigue, but mechanisms are unclear. This secondary analysis of a randomized controlled trial evaluated whether CBT-I led to a significant improvement in fatigue, accounting for change in comorbid symptoms of insomnia, perceived cognitive impairment (PCI), anxiety, and depression. The parent study evaluated the impacts of CBT-I on PCI and insomnia.

METHODS

Cancer survivors with insomnia and PCI were randomized to CBT-I or sleep-self-monitoring waitlist control. Fatigue was measured using the Multidimensional Fatigue Symptom Inventory-Short Form at pre-, mid-, and post-treatment. Significant improvement in fatigue was defined as a reduction of >10.79 points. Insomnia, PCI, anxiety, and depression symptoms were assessed. A linear mixed model evaluated whether CBT-I improved fatigue after adjusting for comorbidities. Mediation analyses examined whether change in comorbidities accounted for the effect of CBT-I on fatigue.

RESULTS

The sample consisted of 132 cancer survivors (77% female, Mage = 60.12 years, 41% breast cancer). There was a significant group-by-time interaction on fatigue, p < .001, with the CBT-I group experiencing a 20.6-point reduction in fatigue compared to 3.7 points in the control. Improvements in fatigue were fully accounted for by improvements in the comorbidities with change in insomnia accounting for 45.3% of the effect observed in fatigue.

CONCLUSIONS

CBT-I resulted in significant improvement in fatigue, and these effects were largely accounted for by changes in insomnia. CBT-I is a robust intervention with efficacy for improving fatigue among cancer survivors.

CLINICAL TRIAL INFORMATION

Online Treatment of Cognitive Impairment and Insomnia in Cancer Survivors, https://clinicaltrials.gov/study/NCT04026048?term=NCT04026048&rank=1, ClinicalTrials.gov ID: NCT04026048.